10,540 results match your criteria Nephritis Lupus


Knockdown of TRIM27 expression suppresses the dysfunction of mesangial cells in lupus nephritis by FoxO1 pathway.

J Cell Physiol 2019 Jan 15. Epub 2019 Jan 15.

Department of Pathology, Hebei Medical University, Key Laboratory of Kidney Diseases of Hebei Province, Shijiazhuang, China.

TRIM27 (tripartite motif-containing 27) is a member of the TRIM (tripartite motif) protein family and participates in a variety of biological processes. Some research has reported that TRIM27 was highly expressed in certain kinds of carcinoma cells and tissues and played an important role in the proliferation of carcinoma cells. However, whether TRIM27 takes part in the progression of lupus nephritis (LN) especially in cells proliferation remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.27810DOI Listing
January 2019

Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey.

Clin Rheumatol 2019 Jan 16. Epub 2019 Jan 16.

Department of Pediatric Rheumatology, Faculty of Medicine, Cukurova University, Adana, Turkey.

Objectives: This study was conducted to analyze clinical characteristics, laboratory data, disease activity, and outcome of juvenile systemic lupus erythematosus (jSLE) patients from southern Turkey.

Methods: Fifty-three patients with jSLE diagnosed according to the revised American College of Rheumatology 1997 criteria between January 2005 and June 2018 were included in the present study.

Results: The median age at the diagnosis was 12. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04433-4DOI Listing
January 2019

Fn14 Deficiency Ameliorates Anti-dsDNA IgG-Induced Glomerular Damage in SCID Mice.

J Immunol Res 2018 16;2018:1256379. Epub 2018 Dec 16.

Department of Dermatology, The Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710004, China.

Many studies have demonstrated that anti-dsDNA IgG is closely associated with lupus nephritis. Recently, it was found that activation of the fibroblast growth factor-inducible 14 (Fn14) signaling pathway damages glomerular filtration barrier in MRL/lpr lupus-prone mice. However, MRL/lpr mice have high titers of serum autoantibodies other than anti-dsDNA IgG. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/jir/2018/1256379/
Publisher Site
http://dx.doi.org/10.1155/2018/1256379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311848PMC
December 2018
1 Read

Systemic Lupus Erythematosus with Linear IgA Bullous Dermatosis and Renal Vascular Lesions: An Extremely Rare Association.

Indian J Nephrol 2018 Nov-Dec;28(6):465-467

Department of Pathology, St. John's Medical College, Bengaluru, Karnataka, India.

We report a rare case of systemic lupus erythematosus presenting initially with cutaneous manifestations of linear IgA bullous dermatosis. Later the patient developed renal abnormalities due to thrombotic microangiopathy and lupus nephritis with inflammatory necrotizing vasculitis. Paucity of immune deposits was observed on Immunofluorescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijn.IJN_200_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309391PMC
January 2019

Urinary Neutrophil Gelatinase-Associated Lipocalin and Urinary Soluble CXCL16 as Biomarkers of Activity in Pediatric Lupus Nephritis.

Indian J Nephrol 2018 Nov-Dec;28(6):427-432

Department of Medical Microbiology and Immunology, Faculty of Medicine, Tanta University, Tanta, Egypt.

One of the challenges of treating patients with lupus nephritis (LN) is to assess disease activity. The aim of this study was to measure the urinary neutrophil gelatinase-associated lipocalin (uNGAL) and urinary soluble chemokine (C-X-C motif) ligand 16 (CXCL16) levels in children and adolescents with systemic lupus erythematosus (SLE) and investigate whether they are elevated in active LN. This study was conducted on 80 patients diagnosed as SLE by the Systemic Lupus International Collaborating Clinics criteria and 60 apparently healthy individuals as controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijn.IJN_265_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309382PMC
January 2019

Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.

J Rheumatol 2019 Jan 15. Epub 2019 Jan 15.

From the Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping; Department of Medicine, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm; Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund; Unit for Clinical Therapy Research (ClinTRID), Karolinska University, Stockholm, Sweden; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Ontario; Division of Rheumatology, Centre Hospitalier Universitaire (CHU) de Québec - Université Laval, Quebec City, Quebec; Division of Rheumatology, Cumming School of Medicine - University of Calgary, Calgary, Alberta; Division of Rheumatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec; Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Department of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea; Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham; Centre for Rheumatology Research, University College, London; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital, King's College London School of Medicine, London; Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland; Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester and UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Foundation Trust, Manchester, UK; Cedars-Sinai/David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California; Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Department of Medicine, State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Feinstein Institute for Medical Research, Manhasset, New York; Division of Rheumatology and Immunology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina; Autoimmunity Institute, Allegheny Health Network, Pittsburgh, Pennsylvania; Northwestern University and Feinberg School of Medicine, Chicago, Illinois; Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia; University of California San Diego School of Medicine, La Jolla, California; Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina; Division of Rheumatology, Columbia University Medical Center, New York, New York, USA; Department of Rheumatology, Center for Rheumatology Research Fossvogur Landspitali University Hospital, Reyjkavik, Iceland; Autoimmune Disease Unit, Department of Internal Medicine, Hospital Universitario Cruces, BioCruces Health Research Institute, University of the Basque Country, Barakaldo; Josep Font Autoimmune Diseases Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain; Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey; Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Rheumatology, Kantousspital, Schaffhausen, Switzerland. This work was supported by grants from the Swedish Rheumatism Association, the County Council of Östergötland, the Swedish Society of Medicine, the King Gustaf V and Queen Victoria's Freemasons foundation, and the King Gustaf V's 80-year anniversary foundation. Dr. Fortin holds a Canada Research Chair on Systemic Autoimmune Rheumatic Diseases. Dr. Bae's work was supported in part by an unrestricted grant (Hanyang University 201600000001387). Dr. Gordon's work was supported by Lupus UK and the NIHR/Wellcome Trust Clinical Research Facility. The Hopkins Lupus Cohort is supported by the US National Institutes of Health (NIH; grant AR43727). The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Bruce is supported by Arthritis Research UK, the NIHR Manchester Biomedical Research Centre and the NIHR/Wellcome Trust Clinical Research Facility at Manchester University National Health Service (NHS) Foundation Trust. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Dr. Jacobsen is supported by the Danish Rheumatism Association (A1028). Dr. Dooley's work was supported by NIH grant RR00046. L. Wirestam, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University; H. Enocsson, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University; T. Skogh, MD, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University; L. Padyukov, MD, PhD, Department of Medicine, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital; A. Jönsen, MD, PhD, Department of Clinical Sciences Lund, Section of Rheumatology, Lund University; M.B. Urowitz, MD, FRCPC, Professor of Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto; D.D. Gladman, MD, FRCPC, Professor of Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto; J. Romero-Diaz, MD, MSc, Instituto Nacional de Ciencias Médicas y Nutrición; S.C. Bae, MD, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; P.R. Fortin, MD, MPH, FRCPC, Professor of Medicine, Division of Rheumatology, CHU de Québec - Université Laval; J. Sanchez-Guerrero, MD, MSc, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto; A.E. Clarke, MD, MSc, Division of Rheumatology, Cumming School of Medicine-University of Calgary; S. Bernatsky, MD, PhD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University Health Centre; C. Gordon, MD, Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham; J.G. Hanly, MD, Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University; D. Wallace, MD, Cedars-Sinai/David Geffen School of Medicine, University of California Los Angeles; D.A. Isenberg, MD, Centre for Rheumatology Research, University College London; A. Rahman, MD, PhD, Centre for Rheumatology Research, University College London; J. Merrill, MD, Department of Clinical Pharmacology, Oklahoma Medical Research Foundation; E. Ginzler, MD, PhD, Department of Medicine, SUNY Downstate Medical Center; G.S. Alarcón, MD, MPH, Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; W.W. Chatham, MD, Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; M. Petri, MD, Department of Rheumatology, Johns Hopkins University School of Medicine; M. Khamashta, MD, Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital, King's College London School of Medicine; C. Aranow, MD, Feinstein Institute for Medical Research; M. Mackay, MD, Feinstein Institute for Medical Research; M.A. Dooley, MD, MPH, Division of Rheumatology and Immunology, Department of Medicine, University of North Carolina; S. Manzi, MD, MPH, Autoimmunity Institute, Allegheny Health Network; R. Ramsey-Goldman, MD, DrPH, Northwestern University and Feinberg School of Medicine; O. Nived, MD, PhD, Department of Clinical Sciences Lund, Section of Rheumatology, Lund University; K. Steinsson, MD, Department of Rheumatology, Center for Rheumatology Research Fossvogur Landspitali University Hospital; A. Zoma, MD, Lanarkshire Centre for Rheumatology, Hairmyres Hospital; G. Ruiz-Irastorza, MD, Autoimmune Disease Unit, Department of Internal Medicine, Hospital Universitario Cruces, BioCruces Health Research Institute, University of the Basque Country; S. Lim, MD, MPH, Division of Rheumatology, Emory University School of Medicine; K. Kalunian, MD, University of California San Diego School of Medicine; M. Inanc, MD, Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University; R. van Vollenhoven, MD, ClinTRID, Karolinska University; M. Ramos-Casals, MD, Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic; D.L. Kamen, MD, Division of Rheumatology, Medical University of South Carolina; S. Jacobsen, MD, DMSc, Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital; C. Peschken, MD, FRCPC, Associate Professor of Medicine, Department of Medicine and Community Health Sciences, University of Manitoba; A. Askanase, MD, MPH, Division of Rheumatology, Columbia University Medical Center; T. Stoll, MD, Department of Rheumatology, Kantousspital; I.N. Bruce, MD, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Foundation Trust; J. Wetterö, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University; C. Sjöwall, MD, PhD, Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University. Address correspondence to Dr. L. Wirestam, AIR/Rheumatology, Department of Clinical and Experimental Medicine, Campus US, Linköping University, SE-581 85 Linköping, Sweden. E-mail: Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 4, 2018.

Objective: In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of patients with recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or are associated with disease activity or certain disease phenotypes.

Methods: We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5 years of followup data available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180713DOI Listing
January 2019

Haemophagocytic lymphohistiocytosis with collapsing lupus podocytopathy as an unusual manifestation of systemic lupus erythematosus with APOL1 double-risk alleles.

BMJ Case Rep 2019 Jan 14;12(1). Epub 2019 Jan 14.

Division of Nephrology, Department of Medicine, Jacobi Medical Center at Albert Einstein College of Medicine, Bronx, New York, USA.

Haemophagocytic lymphohistiocytosis (HLH) is a potentially life-threatening syndrome caused by excessive immune activation. Secondary HLH has been described in autoimmune diseases. We detail the case of a 28-year-old African American woman who developed HLH in the setting of systemic lupus erythematosus with collapsing lupus podocytopathy superimposed on mesangial proliferative lupus nephritis class II. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-227860DOI Listing
January 2019

Fulminant Guillain-Barré syndrome in a patient with systemic lupus erythematosus.

BMJ Case Rep 2019 Jan 14;12(1). Epub 2019 Jan 14.

Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada.

A 45-year-old man with a history of systemic lupus erythematosus presented with progressive weakness and areflexia. Electromyogram revealed reduced motor and sensory amplitudes without demyelinating features. He was clinically diagnosed with the acute motor and sensory axonal neuropathy variant of Guillain-Barré syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-226634DOI Listing
January 2019

Long-term outcomes in lupus patients receiving different renal replacement therapy.

J Microbiol Immunol Infect 2019 Jan 4. Epub 2019 Jan 4.

Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:

Background/purpose: To compare the long-term outcomes and survival rates of patients with end stage renal disease (ESRD) caused by lupus nephritis who received three different modalities of renal replacement therapy, including hemodialysis (HD), peritoneal dialysis (PD), and kidney transplantation (KT).

Methods: We retrospectively analyzed 94 patients with ESRD caused by lupus nephritis. Among these, 42 received HD, 12 received PD, and 40 underwent KT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmii.2018.12.010DOI Listing
January 2019
1 Read

Clinical Outcomes in Patients with Biopsy-proved Diabetic Nephropathy Compared to Isolated Lupus or Crescentic Glomerulonephritis.

Diabetes Res Clin Pract 2019 Jan 11. Epub 2019 Jan 11.

Renal Division, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, No.7, Chung Shan S. Rd., Zhongzheng Dist., Taipei City 10002, Taiwan. Electronic address:

Aims: Diabetic nephropathy (DMN) is usually diagnosed clinically without pathology, and the prognosis of which compared to non-diabetic renal diseases has rarely been investigated especially in ethnic Chinese population. Here we reported the outcome of patients with biopsy-proved DMN compared to those with isolated crescentic glomerulonephritis (GN) or lupus nephritis (LN).

Methods: This retrospective observational study included patients with DMN (n=55), crescentic GN (n=48) and LN (n=82) from an original cohort of 987 adult patients who underwent kidney biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.diabres.2019.01.014DOI Listing
January 2019

Polyomavirus BK, BKV microRNA, and urinary neutrophil gelatinase-associated lipocalin can be used as potential biomarkers of lupus nephritis.

PLoS One 2019 14;14(1):e0210633. Epub 2019 Jan 14.

Kidney Research Center and Department of Nephrology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Objective: Lupus nephritis (LN) frequently progresses to end-stage renal disease. Finding a biomarker for LN and a predictor for the development of chronic kidney disease (CKD) is important for patients with systemic lupus erythematosus (SLE).

Methods: Ninety patients with SLE were divided into biopsy-proven LN (n = 54) and no kidney involvement (non-LN) (n = 36) groups and followed up for 54 months. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210633PLOS
January 2019

microRNAs in chronic kidney disease.

Clin Chim Acta 2019 Jan 10. Epub 2019 Jan 10.

Department of Nephrology, Baoji Central Hospital, No. 8 Jiangtan Road, Baoji, Shaanxi 721008, China. Electronic address:

Chronic kidney disease (CKD) results in high morbidity and mortality worldwide causing a huge socioeconomic burden. MicroRNA (miRNA) exert critical regulatory functions by targeting downstream genes and have been associated with many pathophysiologic processes including CKD. In fact, many studies have shown that the expression of various miRNAs was significantly changed in CKD. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00098981193002
Publisher Site
http://dx.doi.org/10.1016/j.cca.2019.01.008DOI Listing
January 2019
1 Read

Current challenges in the development of new treatments for lupus.

Ann Rheum Dis 2019 Jan 12. Epub 2019 Jan 12.

RILITE Research Institute, Charlottesville, Virginia, USA.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients' quality of life. Despite the plethora of clinical trials for SLE since the turn of the millennium, only one new treatment has been approved for the condition, and the overall pace of successful drug development remains slow. Nevertheless, the myriad of clinical studies has yielded insights that have informed and refined our understanding of eligibility criteria, outcome measures and trial design in SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214530DOI Listing
January 2019

Vitamin D protects podocytes from autoantibodies induced injury in lupus nephritis by reducing aberrant autophagy.

Arthritis Res Ther 2019 Jan 11;21(1):19. Epub 2019 Jan 11.

Department of Nephrology, Research Institute of Nephrology, Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Core Unit of National Clinical Medical Research Center of Kidney Disease, The First Affiliated Hospital of Zhengzhou University, Nephrology, 1 Easten Jianshe Road, Zhengzhou, 450052, Henan, People's Republic of China.

Subject: The aim of this study was to investigate whether vitamin D plays a protective role in podocyte injury induced by autoantibodies purified from the serum of patients with lupus nephritis (LN) via reducing aberrant autophagy.

Methods: Autophagic activities of renal tissues of patients with LN were evaluated under transmission electronic microscope (TEM). Immunoglobulin G (IgG) from patients with LN was purified to induce human podocyte injury, and the role of vitamin D in injury was observed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-018-1803-9DOI Listing
January 2019

Serum Transforming Growth Factor-Beta 1 Level in Egyptian Systemic Lupus Erythematosus Patients.

Arch Rheumatol 2018 Sep 31;33(3):358-366. Epub 2018 Jul 31.

Department of Internal Medicine, Cairo University, Cairo, Egypt.

Objectives: This study aims to assess the role of transforming growth factor-beta 1 (TGF-β1) in systemic lupus erythematosus (SLE).

Patients And Methods: The study included 40 female SLE patients (mean age 25.5±6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5606/ArchRheumatol.2018.6405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328217PMC
September 2018

Seizure and Acute Vision Loss in a Filipino Lupus Patient: A Case of Posterior Reversible Encephalopathy Syndrome with Intraparenchymal Hemorrhage.

Case Rep Med 2018 9;2018:4238676. Epub 2018 Dec 9.

Section of Rheumatology, Department of Medicine, UP-Philippine General Hospital, Manila, Philippines.

Posterior reversible encephalopathy syndrome (PRES) is a rare and poorly understood neurologic condition that has been described in some patients with systemic lupus erythematosus (SLE). Intracerebral hemorrhage is a unique and atypical presentation of PRES and has been described only in a small number of patients with SLE. We present the case of a 33-year-old female, diagnosed with SLE and active nephritis, who was admitted for seizures. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/crim/2018/4238676/
Publisher Site
http://dx.doi.org/10.1155/2018/4238676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304919PMC
December 2018
2 Reads

The role of 5-methoxytryptophan in pediatric-onset lupus nephritis: A retrospective cohort study.

J Microbiol Immunol Infect 2018 Dec 19. Epub 2018 Dec 19.

Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address:

Background: This clinical study investigates the role of 5-methoxytryptophan (5-MTP) in pediatric systemic lupus erythematosus (SLE), with a particular interest in lupus nephritis (LN).

Patients And Methods: One hundred ten children with SLE were enrolled in the cohort study. Among the patients, seventy-seven (70%) had active LN and thirty-three (30%) were not present with LN during their first visit to the clinic. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S16841182183007
Publisher Site
http://dx.doi.org/10.1016/j.jmii.2018.12.003DOI Listing
December 2018
1 Read

One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants.

Adv Anat Pathol 2019 Jan 7. Epub 2019 Jan 7.

Kidney Diseases Branch, NIDDK, NIH, Bethesda.

Genetic variants in APOL1, encoding apolipoprotein L1, are major drivers of glomerular disease in peoples of sub-Saharan African descent. APOL1-associated primary glomerular diseases include focal segmental glomerulosclerosis, human immunodeficiency virus-associated nephropathies, and arterionephrosclerosis. Other conditions where APOL1 variants affect outcomes include membranous nephropathy, lupus nephritis, diabetic nephropathy, preeclampsia, and kidney transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000221DOI Listing
January 2019

IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL- Mice.

J Am Soc Nephrol 2019 Jan 8. Epub 2019 Jan 8.

Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and

Background: In people with SLE and in the MRL- lupus mouse model, macrophages and autoantibodies are central to lupus nephritis. IL-34 mediates macrophage survival and proliferation, is expressed by tubular epithelial cells (TECs), and binds to the cFMS receptor on macrophages and to a newly identified second receptor, PTPRZ.

Methods: To investigate whether IL-34-dependent intrarenal and systemic mechanisms promote lupus nephritis, we compared lupus nephritis and systemic illness in MRL- mice expressing IL-34 and IL-34 knockout (KO) MRL- mice. Read More

View Article

Download full-text PDF

Source
http://www.jasn.org/lookup/doi/10.1681/ASN.2018090901
Publisher Site
http://dx.doi.org/10.1681/ASN.2018090901DOI Listing
January 2019
3 Reads

Bradykinin 1 receptor blockade subdues systemic autoimmunity, renal inflammation, and blood pressure in murine lupus nephritis.

Arthritis Res Ther 2019 Jan 8;21(1):12. Epub 2019 Jan 8.

Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.

Objective: The goal of this study was to explore the role of bradykinins and bradykinin 1 receptor (B1R) in murine lupus nephritis.

Methods: C57BL/6 and MRL/lpr mice were compared for renal expression of B1R and B2R by western blot and immunohistochemistry. MRL/lpr lupus-prone mice were administered the B1R antagonist, SSR240612 for 12 weeks, and monitored for blood pressure, proteinuria, renal function, and serum autoantibodies. Read More

View Article

Download full-text PDF

Source
https://arthritis-research.biomedcentral.com/articles/10.118
Publisher Site
http://dx.doi.org/10.1186/s13075-018-1774-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325757PMC
January 2019
1 Read

Identification of Low-Abundance Urinary Biomarkers in Lupus Nephritis using Electrochemiluminescence Immunoassays.

Arthritis Rheumatol 2019 Jan 7. Epub 2019 Jan 7.

Department Biomedical Engineering, University of Houston, Houston, TX.

Objective: To identify low abundance urinary protein biomarkers in Lupus nephritis (LN), this study aims to investigate the utility of a more sensitive platform using electrochemiluminescence (ECL).

Methods: 48 human urine samples across 2 independent cohorts (each matched for age/gender/race and containing 8 active LN (rSLEDAI>0), 8 inactive lupus (rSLEDAI=0), and 8 healthy controls) were tested using a pre-existing 40-plex ECL panel. A custom 5-plex ECL panel was then developed for further validation studies and used to test 140 urine samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40813DOI Listing
January 2019

Sodium 4-phenylbutyrate treatment protects against renal injury in NZBWF1 mice.

Clin Sci (Lond) 2019 Jan 7. Epub 2019 Jan 7.

Department of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States

Systemic lupus erythematosus (SLE) is an autoimmune disease predominantly affecting women and often leading to lupus nephritis and kidney damage. Endoplasmic reticulum (ER) stress has been implicated in several forms of kidney disease, but whether ER stress contributes to renal injury in SLE is unknown. To investigate this, a small molecule chaperone, sodium 4-phenylbutyrate (4-PBA), was administered to the NZBWF1 mouse model of SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/CS20180562DOI Listing
January 2019

Protective Effects of Epigallocatechin-3-Gallate from Green Tea in Various Kidney Diseases.

Adv Nutr 2019 Jan 5. Epub 2019 Jan 5.

Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Kidney diseases are common health problems worldwide. Various etiologies (e.g. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/advances/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/advances/nmy077DOI Listing
January 2019
1 Read

Re-biopsy in lupus nephritis.

Ann Transl Med 2018 Nov;6(Suppl 1):S41

Renal Division, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.09.47DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291576PMC
November 2018

NF-kB signaling in myeloid cells mediates the pathogenesis of immune-mediated nephritis.

J Autoimmun 2019 Jan 3. Epub 2019 Jan 3.

Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA; Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA. Electronic address:

Immune-mediated glomerulonephritis is a serious end organ pathology that commonly affects patients with systemic lupus erythematosus (SLE). A classic murine model used to study lupus nephritis (LN) is nephrotoxic serum nephritis (NTN), in which mice are passively transferred nephrotoxic antibodies. We have previously shown that macrophages are important in the pathogenesis of LN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaut.2018.11.004DOI Listing
January 2019

Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.

Ann Transl Med 2018 Dec;6(23):452

Department of Rheumatology, Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China.

Background: Systemic lupus erythematosus (SLE) patients have tendencies of accelerated atherosclerosis (AS) which can only partly be explained by traditional cardiovascular disease (CVD) risk factors. Imbalanced inflammation also plays a vital role. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new therapeutic target for AS for its dual mechanisms in lipids and inflammation. Read More

View Article

Download full-text PDF

Source
http://atm.amegroups.com/article/view/22301/21985
Publisher Site
http://dx.doi.org/10.21037/atm.2018.11.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312819PMC
December 2018
2 Reads

Early outcomes in kidney transplant recipients with systemic lupus erythematosus.

Rheumatol Int 2019 Jan 2. Epub 2019 Jan 2.

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Col. Sección XVI, Tlalpan, CP 14000, Mexico City, Mexico.

Kidney transplant (KT) is the best treatment for patients who progress to end-stage renal disease. Short-term outcomes in patients with systemic lupus erythematosus (SLE) following KT are not well known. To describe the postoperative outcomes and complications in SLE patients undergoing KT, we conducted a case-control study from 2010 to 2015 including SLE recipients compared to non-SLE controls matched by age and sex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-018-4234-7DOI Listing
January 2019
1 Read

Decreased α7nAChR mRNA levels in peripheral blood monocytes are associated with enhanced inflammatory cytokine production in patients with lupus nephritis.

Biomed Pharmacother 2018 Dec 26;111:359-366. Epub 2018 Dec 26.

Urology Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China. Electronic address:

The cholinergic anti-inflammatory pathway modulates cytokine release by activating alpha-7 nicotinic acetylcholine receptors (α7nAChR) in monocytes/macrophages. We aimed to determine the role of α7nAChR in lupus nephritis (LN). We enrolled 36 inactive and 35 active LN patients, 34 primary glomerulonephritis patients, and 35 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2018.12.093DOI Listing
December 2018
1 Read

Pattern of glomerular disease and clinicopathological correlation: A single-center study from Eastern Nepal.

Saudi J Kidney Dis Transpl 2018 Nov-Dec;29(6):1410-1416

Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal.

The pattern of glomerular disease varies worldwide. In the absence of kidney disease/kidney biopsy registry in Nepal, the exact etiology of different forms of glomerular disease is primarily unknown in our country. We analyzed 175 cases of renal biopsies performed from September 2014 to August 2016 in Internal Medicine Ward at B. Read More

View Article

Download full-text PDF

Source
http://www.sjkdt.org/text.asp?2018/29/6/1410/248302
Publisher Site
http://dx.doi.org/10.4103/1319-2442.248302DOI Listing
December 2018
5 Reads

Clinicopathological profile of pediatric renal biopsies at a tertiary care hospital, Pakistan.

Saudi J Kidney Dis Transpl 2018 Nov-Dec;29(6):1403-1409

The Kidney Center, Karachi, Pakistan.

Renal biopsy is an important tool for the diagnosis of acute and chronic glomerular diseases in children. We aimed to analyze the spectrum of clinical indications and histopathological patterns (HPP) in children who underwent renal biopsy (RB). This is a retrospective review of case records of 108 renal biopsies carried out from January 2010 to December 2015 at the Pediatric Nephrology Department, National Institute of Child Health Karachi, Pakistan. Read More

View Article

Download full-text PDF

Source
http://www.sjkdt.org/text.asp?2018/29/6/1403/248290
Publisher Site
http://dx.doi.org/10.4103/1319-2442.248290DOI Listing
December 2018
9 Reads

Spectrum of glomerular diseases in Arab countries: A systematic review.

Saudi J Kidney Dis Transpl 2018 Nov-Dec;29(6):1256-1266

Department of Allied Health Sciences, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Sultanate of Oman.

According to the best of our knowledge, there is no review compiling incidence of glomerular disease in all Arab countries. Most of the Arab countries do not have a national renal biopsy registry. In addition, there is scanty data available on the epidemiology of glomerular diseases in Arab countries. Read More

View Article

Download full-text PDF

Source
http://www.sjkdt.org/text.asp?2018/29/6/1256/248285
Publisher Site
http://dx.doi.org/10.4103/1319-2442.248285DOI Listing
December 2018
3 Reads

Plasma sMer, sAxl and GAS6 levels correlate with disease activity and severity in lupus nephritis.

Eur J Clin Invest 2018 Dec 27:e13064. Epub 2018 Dec 27.

Department of Nephrology, First Affiliated Hospital of Harbin Medical University, Harbin, China.

Objective: The purpose of this study is to determine whether TAM receptors and ligands associated with the activity and severity of lupus nephritis.

Methods: Clinical data were statistically analysed and studied in 122 SLE patients, diagnosed from 2013 to 2016 in First Hospital Affiliated to Harbin Medical University. Levels of TAM receptors and ligands in the plasma of 122 SLE patients were measured by ELISA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/eci.13064DOI Listing
December 2018
1 Read

The potential diagnostic utility of coexpression of Ki-67 and P53 in the renal biopsy in pediatric lupus nephritis.

Int J Nephrol Renovasc Dis 2018 12;11:343-350. Epub 2018 Dec 12.

Santa Monica College, Santa Monica, CA, USA.

Background: The proliferative activity as well as apoptosis has been suggested to play a role in the pathogenesis of lupus nephritis (LN). The aim of the study was to investigate the coexpression of Ki-67-triggered marked proliferation and P53-induced apoptosis in renal biopsy of childhood lupus nephritis (cLN) and to compare the coexpression of proliferative and apoptotic indices between different subgroups and clinicopathologic patterns of renal disease.

Methods: Renal biopsy specimens of 33 children with lupus nephritis (LN) and 10 healthy subjects were retrospectively evaluated. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/the-potential-diagnostic-utility-o
Publisher Site
http://dx.doi.org/10.2147/IJNRD.S175481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296180PMC
December 2018
4 Reads

A suppurative thyroiditis and perineal subcutaneous abscess related with aspergillus fumigatus: a case report and literature review.

BMC Infect Dis 2018 Dec 27;18(1):702. Epub 2018 Dec 27.

Department of Critical Care Medicine, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, People's Republic of China.

Background: Invasive aspergillosis is a complication in immunocompromised patients and commonly detected in patients with hematological malignancies, which mostly affect the lungs. Because of its high iodine content, rich blood supply and capsule, the thyroid is considered to be less prone to microbial invasion thus most infectious thyroiditis cases are caused by bacteria. However, a few case reports have described thyroid gland aspergilloses, most of which were due to disseminated invasive aspergillosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12879-018-3617-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307113PMC
December 2018
1 Read

Malignancy in Systemic Lupus Erythematosus (SLE) Patients

Asian Pac J Cancer Prev 2018 Dec 25;19(12):3551-3555. Epub 2018 Dec 25.

Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, Kuala Lumpur, Malaysia. Email:

Background: Malignancies are among the leading causes of death in Systemic Lupus Erythematosus (SLE) patients with studies reporting a higher prevalence of malignancy in SLE patients compared to the general population. We wanted to determine the frequency of cancer in a cohort of SLE patients and identify its associated risk factors. Methods: Cross-sectional study involving SLE patients attending the nephrology outpatient clinic, Universiti Kebangsaan Malaysia Medical Centre between January and June 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31557/APJCP.2018.19.12.3551DOI Listing
December 2018
1 Read

ANCA-Associated Necrotizing Glomerulonephritis Overlapping with Mesangial Proliferative Lupus Nephritis Refractory to Plasmapheresis, Steroid Pulse Therapy, and a Combination of Mycophenolate Mofetil and Rituximab.

Case Rep Rheumatol 2018 19;2018:3076806. Epub 2018 Nov 19.

Division of Rheumatology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.

Necrotizing glomerulonephritis (GN) associated with antineutrophil cytoplasmic antibody (ANCA) has been increasingly recognized in the context of class III or IV lupus nephritis (LN), hereafter designated as . While this subset of GN appears to portend an unfavorable renal outcome, it is not clear whether it represents a distinct entity and benefits from a more aggressive therapy. We report a 78-year-old woman who presented with rapidly progressive GN and was found to have a double-stranded DNA (dsDNA) antibody, hypocomplementemia, antiphospholipid antibody, and strongly positive myeloperoxidase antibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3076806DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276453PMC
November 2018

Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus.

Clin Immunol 2018 Dec 19;200:1-9. Epub 2018 Dec 19.

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan. Electronic address:

Memory B cells are increased in systemic lupus erythematosus (SLE) cases, but the qualitative abnormalities and induction mechanism of these cells are unclear. Here, we subclassified B cells by their chemokine receptor expression and investigated their induction mechanism. The peripheral blood of patients with SLE showed higher levels of CXCR5 and CXCR3 B cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2018.12.017DOI Listing
December 2018
1 Read

Response to: 'OCTA, a sensitive screening for asymptomatic retinopathy, raises alarm over systemic involvements in patients with SLE' by Mizuno et .

Ann Rheum Dis 2018 Dec 20. Epub 2018 Dec 20.

Rheumatology, Allergology and Clinical Immunology, Department of 'Medicina dei Sistemi', University of Rome Tor Vergata, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214796DOI Listing
December 2018
3 Reads

Myocardial remodeling after kidney transplantation: a case report.

BMC Nephrol 2018 Dec 20;19(1):372. Epub 2018 Dec 20.

Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.

Background: Lupus nephritis (LN) is one of the most common manifestations of systemic lupus erythematosus (SLE) and is often the most serious organ complication and the cause of premature death of such a patient. Most of other organs and systems can be also affected. A typical complication is a cardiovascular involvement leading to the development of heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-018-1185-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302396PMC
December 2018
2 Reads

Allogeneic adipose-derived stem cells suppress mTORC1 pathway in a murine model of systemic lupus erythematosus.

Lupus 2018 Dec 20:961203318819131. Epub 2018 Dec 20.

1 Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Objective: The aim of our study was to investigate the efficacy of adipose-derived stem cells (ADSC) transplantation in systemic lupus erythematosus (SLE) and to determine the mechanism of ADSC transplantation.

Methods: B6.MRL/lpr mice were administered ADSC intravenously every week from age 28 to 31 weeks, while the lupus control group and the normal control received phosphate buffered solution (PBS) on the same schedule. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318819131DOI Listing
December 2018
1 Read

The association between serum prolactin levels and interleukin-6 and systemic lupus erythematosus activity.

Reumatismo 2018 Dec 20;70(4):241-250. Epub 2018 Dec 20.

University Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur.

Based on the recent evidence of association between hyperprolactinemia and systemic lupus erythematosus disease activity (SLEDAI), a study was conducted to analyze the association of hyperprolactinemia with lupus nephritis disease activity. In this cross-sectional study, the analysis was conducted on SLE patients who visited the University Kebangsaan Malaysia Medical Centre (UKMMC) Nephrology Clinic from August 2015 till February 2016. The disease activity was measured using the SLEDAI score, with more than 4 indicating active lupus nephritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/reumatismo.2018.1075DOI Listing
December 2018
1 Read

Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort.

Arthritis Res Ther 2018 Dec 19;20(1):280. Epub 2018 Dec 19.

Complexo Hospitalario Universitario de Vigo, Vigo, Spain.

Background: The purpose of this study was to assess the prevalence, associated factors, and impact on mortality of primary respiratory disease in a large systemic lupus erythematosus (SLE) retrospective cohort.

Methods: All adult patients in the RELESSER-TRANS (Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology [SER], cross-sectional phase) registry were retrospectively investigated for the presence of primary pleuropulmonary manifestations.

Results: In total 3215 patients were included. Read More

View Article

Download full-text PDF

Source
https://arthritis-research.biomedcentral.com/articles/10.118
Publisher Site
http://dx.doi.org/10.1186/s13075-018-1776-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299951PMC
December 2018
5 Reads

Clinical usefulness of serum levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio to rule out preeclampsia in women with new-onset lupus nephritis during pregnancy.

CEN Case Rep 2018 Dec 18. Epub 2018 Dec 18.

Department of Obstetrics and Gynecology, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, 329-0498, Japan.

Measurement of the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio may be clinically useful to discriminate systemic lupus erythematosus (SLE) from preeclampsia. Here, we present a pregnant woman with new-onset SLE with hypertension, with the measurement of the sFlt-1/PlGF ratio during pregnancy. A 31-year-old Japanese nulliparous woman, who had been diagnosed with idiopathic thrombocytopenic purpura at 10 years, had a systolic blood pressure of 120 mmHg and was negative for proteinuria at 12 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13730-018-0373-7DOI Listing
December 2018

Systemic lupus erythematosus: state of the art on clinical practice guidelines.

RMD Open 2018 27;4(2):e000793. Epub 2018 Nov 27.

Assistance Publique-Hôpitaux de Paris (AP-HP), Internal Medicine Department, Cochin Hospital, Referral center for rare autoimmune and systemic diseases, Paris, France.

Systemic lupus erythematosus (SLE) is the paradigm of systemic autoimmune diseases characterised by a wide spectrum of clinical manifestations with an unpredictable relapsing-remitting course. The aim of the present work was to identify current available clinical practice guidelines (CPGs) for SLE, to provide their review and to identify physicians' and patients' unmet needs. Twenty-three original guidelines published between 2004 and 2017 were identified. Read More

View Article

Download full-text PDF

Source
http://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2018-00079
Publisher Site
http://dx.doi.org/10.1136/rmdopen-2018-000793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269635PMC
November 2018
6 Reads

REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A).

Ann Rheum Dis 2019 Feb 18;78(2):238-248. Epub 2018 Dec 18.

Laboratory of Immune Regulation and Tolerance, Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece

Objectives: The release of neutrophil extracellular traps (NETs) represents a novel neutrophil effector function in systemic lupus erythematosus (SLE) pathogenesis. However, the molecular mechanism underlying NET release and how NETs mediate end-organ injury in SLE remain elusive.

Methods: NET formation and NET-related proteins were assessed in the peripheral blood and biopsies from discoid lupus and proliferative nephritis, using immunofluorescence, immunoblotting, quantitative PCR and ELISA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-213181DOI Listing
February 2019
1 Read

[Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case report].

Beijing Da Xue Xue Bao Yi Xue Ban 2018 Dec;50(6):1102-1107

Department of Rheumatology and Immunology, Peking University First Hospital, Beijing 100034, China.

This case report concerns a 22-year-old woman who had been diagnosed with systemic lupus erythematosus (SLE). She had intermittent fever, butterfly erythema, photosensitivity, oral ulcers, and multiple arthralgia in the past seven years, but she did not adhere to regular treatments. The edema of the lower extremities and face aggravated in the recent two weeks, so she was admitted to our Department of Rheumatology and Clinical Immunology. Read More

View Article

Download full-text PDF

Source
December 2018

[Efficacy of mesenchymal stem cells on systemic lupus erythematosus:a meta-analysis].

Beijing Da Xue Xue Bao Yi Xue Ban 2018 Dec;50(6):1014-1021

Department of Rheumatology and Immunology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.

Objective: Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvement and several typical autoantibodies. Mesenchymal stem cells (MSC) are multipotent stem cells with low immunogenicity that can differentiate into various kinds of cells, such as bone, cartilage, fat and skin tissue. MSC have immunomodulatory and reparative properties through interactions with immune cells. Read More

View Article

Download full-text PDF

Source
December 2018

[Study of bone mineral density and serum bone turnover markers in newly diagnosed systemic lupus erythematosus patients].

Beijing Da Xue Xue Bao Yi Xue Ban 2018 Dec;50(6):998-1003

Department of Rheumatology and Immunology, Peking University People's Hospital,Beijing 100044, China.

Objective: To investigate the changes of bone mineral density (BMD) and serum bone turnover factor in newly diagnosed systemic lupus erythematous (SLE) patients.

Methods: Eighty newly diagnosed SLE patients and 80 age and gender matched healthy controls were enrolled. None of the SLE patients had ever received glucocorticoid, immunosuppressive agents or vitamin D. Read More

View Article

Download full-text PDF

Source
December 2018

The immune podocyte.

Curr Opin Rheumatol 2018 Dec 17. Epub 2018 Dec 17.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Purpose Of Review: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus and is characterized by proteinuria and renal failure. Proteinuria is a marker of poor prognosis and is attributed to podocyte loss and dysfunction. It is often debated whether these cells are innocent bystanders or active participants in the pathogenesis of glomerulonephritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000578DOI Listing
December 2018
1 Read

Remission of proteinuria under therapeutic intervention and the renal outcomes in Japanese patients with lupus nephritis class III and IV.

Mod Rheumatol 2018 Dec 17:1-17. Epub 2018 Dec 17.

a Division of Nephrology and Hypertension, Department of Internal Medicine , The Jikei University School of Medicine , Tokyo , Japan.

Background: Recent studies have identified the significance of proteinuria levels after initial induction therapies on the renal outcomes in patients with proliferative lupus nephritis, but the issue has not been evaluated in Japanese patients.

Methods: Based on the ISN/RPS classification, only patients diagnosed as lupus nephritis class III or IV were included. The remission of proteinuria twelve months after diagnosis, as well as the clinicopathological features at diagnosis, on renal outcomes was examined retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14397595.2018.1558948DOI Listing
December 2018